Publication:
Phenformin as an Anticancer Agent: Challenges and Prospects.

Loading...
Thumbnail Image

Date

2019-07-05

Authors

García Rubiño, Mª Eugenia
Carrillo, Esmeralda
Ruiz Alcalá, Gloria
Domínguez-Martín, Alicia
A Marchal, Juan
Boulaiz, Houria

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Currently, there is increasing evidence linking diabetes mellitus (especially type 2 diabetes mellitus) with carcinogenesis through various biological processes, such as fat-induced chronic inflammation, hyperglycemia, hyperinsulinemia, and angiogenesis. Chemotherapeutic agents are used in the treatment of cancer, but in most cases, patients develop resistance. Phenformin, an oral biguanide drug used to treat type 2 diabetes mellitus, was removed from the market due to a high risk of fatal lactic acidosis. However, it has been shown that phenformin is, with other biguanides, an authentic tumor disruptor, not only by the production of hypoglycemia due to caloric restriction through AMP-activated protein kinase with energy detection (AMPK) but also as a blocker of the mTOR regulatory complex. Moreover, the addition of phenformin eliminates resistance to antiangiogenic tyrosine kinase inhibitors (TKI), which prevent the uncontrolled metabolism of glucose in tumor cells. In this review, we evidence the great potential of phenformin as an anticancer agent. We thoroughly review its mechanism of action and clinical trial assays, specially focusing on current challenges and future perspectives of this promising drug.

Description

MeSH Terms

Animals
Antineoplastic Agents
Diabetes Mellitus, Type 2
Humans
Models, Biological
Neoplasms
Phenformin
Risk Factors

DeCS Terms

CIE Terms

Keywords

biguanides, cancer, cancer stem cells, diabetes type 2, phenformin

Citation